文献速递药物不良反应与药物警戒

雷尼替丁与癌症风险:FAERS数据分歧的不成比例分析与比较安全性研究的系统综述

Disproportionality Analysis of FAERS Data Divergence and a Systematic Review of Comparative Safety Studies: Lessons Learned from the Example of Ranitidine and Cancer Risk.
PubMed 文献 · Drug Saf · 2026-10-10

该研究通过FAERS和JADER数据库的不成比例分析及比较安全性研究系统综述,评估雷尼替丁相关癌症信号。研究发现FAERS中癌症报告激增主要与NMDA监管警示相关,而非内在致癌性;活性对照和时间限制分析可显著减弱信号,JADER中PRR从3.54降至0.92提示前兆偏倚。系统综述显示大多数大型队列研究未发现总体或部位特异性癌症风险增加。

要点

  • 雷尼替丁癌症信号主要归因于NMDA相关监管警示而非药物内在致癌性。
  • 活性对照与时间限制分析可显著减弱或消除虚假信号。
  • JADER中疑似药物报告PRR=3.54,纳入所有涉及类型后降至0.92,提示前兆偏倚。

核心结论

  • 自发报告系统中雷尼替丁癌症信号主要源于NMDA相关监管警示而非内在致癌性。
  • 活性对照与时间限制分析及比较安全性研究系统综述对避免药物警戒误导性推断至关重要。

研究设计与样本

  • 回顾性不成比例分析,使用FAERS和JADER数据库。
  • 采用四种互补算法(PRR、ROR、IC、EBGM)进行信号检测,并设活性对照(法莫替丁)和时间限制(召回前后)分析。
  • 同时进行对比安全性研究的系统综述。

主要发现

  • FAERS中2020-21年雷尼替丁癌症报告达140,985份,占所有报告癌症病例的三分之二以上。
  • 多数报告由消费者提交,地理上集中于受监管措施和诉讼影响的地区。
  • 全FAERS数据库无限制分析识别出多种癌症的高强度信号,尤其胃肠道和泌尿生殖系统癌症。
  • 活性对照和时间限制分析中信号显著减弱或缺失,雷尼替丁与法莫替丁报告特征趋同。
  • JADER分析中,疑似药物报告雷尼替丁-癌症信号显著(PRR=3.54),但分析所有涉及类型时完全消失(PRR=0.92)。

关键数值与推荐

  • JADER中疑似药物报告PRR=3.54,所有涉及类型分析PRR=0.92。
  • 系统综述中多数大型队列研究显示总体或部位特异性癌症风险未增加。

临床怎么用

  • 药物警戒评估中应采用活性对照和时间限制分析以避免误导性推断。
  • 结合比较安全性研究系统综述综合判断信号,减少前兆偏倚影响。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ranitidine, a histamine-2 receptor antagonist, was withdrawn globally in 2020 following the detection of N-nitrosodimethylamine (NMDA), a probable human carcinogen. OBJECTIVE: We aimed to assess advanced pharmacovigilance bias-mitigation approaches by evaluating ranitidine-associated cancer signals in the FDA Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases alongside a systematic review of comparative safety studies. METHODS: A retrospective disproportionality analysis was conducted using the FAERS and the JADER databases. Signal detection was performed using four complementary algorithms (proportional reporting ratio (PRR), reporting odds ratio, information component, and empirical Bayes geometric mean), with an active comparator (famotidine) and time-restricted (pre- and post-recall) analyses, and a systematic review of comparative safety studies was also conducted. RESULTS: A pronounced surge in cancer reporting was observed for ranitidine, with 140,985 reports recorded in FAERS during 2020-21, accounting for more than two thirds of all reported cancer cases. Most reports were consumer submitted and geographically clustered in regions affected by regulatory actions and litigation. Unrestricted analyses of the full FAERS database identified high-magnitude signals for multiple cancers, particularly gastrointestinal and genitourinary cancers. However, these signals were markedly attenuated or absent in active-comparator and time-restricted analyses, with convergence observed in the reporting profiles of ranitidine and famotidine. In the JADER analysis, a significant ranitidine-cancer signal among suspected drug reports (PRR = 3.54) disappeared completely when all involvement types were analyzed (PRR = 0.92), indicating that the observed association likely reflects protopathic bias, rather than a true carcinogenic effect. The systematic review revealed heterogeneous findings, with most large cohort studies demonstrating no increased risk of overall or site-specific cancers. CONCLUSIONS: The observed cancer signals for ranitidine in spontaneous reporting systems were predominantly attributable to the NMDA related regulatory alerts rather than intrinsic carcinogenicity. Active-comparator and time-restricted analyses, together with systematic reviews of comparative safety studies, are essential to avoid misleading inferences in pharmacovigilance assessments.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Rathod M, Kadari M, Mohan HR, et al. Disproportionality Analysis of FAERS Data Divergence and a Systematic Review of Comparative Safety Studies: Lessons Learned from the Example of Ranitidine and Cancer Risk. Drug Saf. 2026. PMID: 42859294. doi:10.1007/s40264-026-01730-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。